Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dashboard-driven individualized infliximab dosing versus standard dosing in acute severe ulcerative colitis
2018-003524-36Phase 4Completed
- Sponsor
- Amsterdam UMC
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in autoimmune colitis (2 arms), sponsored by Amsterdam UMC. Primary endpoint: Treatment success at week 6. Started Nov 2018; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-003524-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003524-36.